Portfolio company
Valink Therapeutics
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
6 investors
Sectors
About
Valink Therapeutics develops next-generation bispecific antibody-drug conjugates to treat solid tumours for cancer patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
TwoStep Therapeutics
The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.
Callio Therapeutics
The company develops multi-payload antibody-drug conjugates to treat cancer patients.
Clinical stage immunotherapy company
This company develops next-generation antibody-drug conjugates to treat patients with solid tumor malignancies.
Kivu Bioscience
Kivu Bioscience develops next-generation antibody-drug conjugates to provide oncology treatments for cancer patients while reducing off-target side effects.
Profound Bio
This clinical-stage biotechnology company develops antibody-drug conjugates and targeted therapies for patients with solid tumors and hematological malignancies.
Alphina Therapeutics
This biotechnology company develops antibody-drug conjugates with novel payloads to treat solid tumours for healthcare providers and cancer patients.
Angiex
This company develops antibody-drug conjugates for clinicians and pharmaceutical partners to treat solid cancers and vascular diseases.
Mablink Bioscience
This biotechnology firm develops antibody-drug conjugates for pharmaceutical companies to treat cancer using a proprietary hydrophilic linker platform.